Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could liver cancer patients skip the hospital stay? new trial tests outpatient care

NCT ID NCT06990659

Knowledge-focused Sponsor: University Hospital, Angers Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jul 17, 2026 · Updated 5 times

Summary

This study tests whether people with liver cancer can be safely treated as outpatients instead of staying in the hospital after a procedure that delivers treatment directly to the liver's blood supply. About 206 patients will be randomly assigned to either outpatient or standard inpatient care. Researchers will measure patient satisfaction, safety, and costs over 7 months to see which approach works better.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could show that outpatient care is just as safe and more satisfying for liver cancer patients, potentially changing standard hospital practices.
What could go wrong
This is a care organization study, not a drug trial, so it won't directly improve cancer outcomes. Results may not apply to all hospitals or patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 206 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * HCC or iCCA diagnosed according to the criteria of the European Association for the Study of the Liver (2024) or histologically proven. * Patient with HCC or iCCA eligible for intra-arterial treatment (transarterial chemoembolization \[TACE\] or transarterial radioembolization \[TARE\]), with no prior intra-arterial treatment of the same type as the one planned in the trial: * no prior TACE for patients included for TACE; * no prior TARE for patients included for TARE. Prior intra-arterial treatment of the other type is allowed (prior TACE before TARE, or prior TARE before TACE). Prior non-intra-arterial treatments are allowed. * If TACE is proposed at the multidisciplinary tumour board (RCP): * Patient Child-Pugh \< B8 * Single or multiple HCC * Absence of lobar or truncal portal obstruction * Absence of bile duct dilatation * If treatment by TARE proposed in RCP: * Absence of truncal portal tumor invasion * Uni-lobar tumor invasion (except for centrohepatic iCCA) * Total bilirubin \< 20 mg/l (or 35 µmol/L) * Patient affiliated to or benefiting from a social security scheme * Patient having signed an informed consent form Exclusion Criteria: * Technical contraindication or morphological elements of predictable technical difficulty * Planned combined same-day therapeutic strategies at the index procedure (e.g., TACE combined with percutaneous ablation) are not allowed; sequential (non-same-day) treatments are allowed. * Chronic renal insufficiency (Clairance \< 30 ml/min) * Known allergy to a contrast agent or chemotherapy agent * inability to participate in ambulatory care (inability to understand and follow discharge instructions, lack of reliable telephone access, absence of a responsible accompanying adult for the first night after discharge, or inability to access urgent care in a timely manner if symptoms occur) * Patient previously included in the study * Patient who, for psychological, social, family or geographical reasons, could not be regularly monitored, patient who, for psychological, social, family or geographical reasons, could not be followed regularly * Concomitant disease or severe uncontrolled clinical situation * Severe uncontrolled infection * Pregnant, breast-feeding or parturient woman * Person deprived of liberty by judicial or administrative decision * Person under compulsory psychiatric care * Person under a legal protection measure * Person unable to give consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepato cellular carcinoma (HCC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cholangiocarcinoma hepatocellular carcinoma intrahepatic cholangiocarcinoma Patient Satisfaction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepato cellular carcinoma (HCC) Intrahepatic cholangiocarcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    19 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hospital of Avicennes (AP-HP)

    RECRUITING

    Bobigny, France

  • Hospital of Beaujon (AP-HP)

    RECRUITING

    Clichy, 92110, France

  • Hospital of Cochin (AP-HP)

    RECRUITING

    Paris, 75014, France

  • Hospital of Pitié-Salpétrière (AP-HP)

    RECRUITING

    Paris, 75013, France

  • Hospital of Vendée

    RECRUITING

    La Roche-sur-Yon, 85925, France

  • Institut Gustave Roussy (IGR)

    RECRUITING

    Villejuif, 94805, France

  • Saint-Antoine Hospital (AP-HP)

    RECRUITING

    Paris, 75012, France

  • Saint-Joseph Hospital

    RECRUITING

    Marseille, 13008, France

  • University hospital of Amiens

    RECRUITING

    Amiens, 80054, France

  • University hospital of Angers

    RECRUITING

    Angers, 49933, France

  • University hospital of Besançon

    RECRUITING

    Besançon, 25030, France

  • University hospital of Brest

    RECRUITING

    Brest, 29609, France

  • University hospital of Grenoble-Alpes

    RECRUITING

    La Tronche, 38700, France

  • University hospital of Marseille (AP-HM)

    RECRUITING

    Marseille, 13005, France

  • University hospital of Montpellier

    NOT_YET_RECRUITING

    Montpellier, 34090, France

  • University hospital of Nantes

    NOT_YET_RECRUITING

    Nantes, 44093, France

  • University hospital of Nice

    RECRUITING

    Nice, 06202, France

  • University hospital of Toulouse

    RECRUITING

    Toulouse, 31059, France

  • Univesity hospital of Bordeaux

    NOT_YET_RECRUITING

    Pessac, 33607, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.